News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
572,783 Results
Type
Article (45812)
Company Profile (132)
Press Release (526839)
Section
Business (159800)
Career Advice (2454)
Deals (29962)
Drug Delivery (119)
Drug Development (73688)
Employer Resources (149)
FDA (16255)
Job Trends (12626)
News (287401)
Policy (31207)
Tag
2024 BioCapital Digital (5)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (2)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (2)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (1)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (5)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2403)
Academic (1)
Accelerated approval (3)
Adcomms (29)
Allergies (71)
Alliances (40326)
ALS (77)
Alzheimer's disease (1391)
Antibody-drug conjugate (ADC) (119)
Approvals (16206)
Artificial intelligence (214)
Autoimmune disease (13)
Automation (10)
Bankruptcy (313)
Best Places to Work (9660)
BIOSECURE Act (21)
Biosimilars (99)
Biotechnology (82)
Bladder cancer (55)
Brain cancer (24)
Breast cancer (224)
Cancer (1773)
Cardiovascular disease (142)
Career advice (2035)
Career pathing (31)
CAR-T (135)
Cell therapy (380)
Cervical cancer (15)
Clinical research (59479)
Collaboration (657)
Compensation (392)
Complete response letters (28)
COVID-19 (2628)
CRISPR (36)
C-suite (173)
Cystic fibrosis (95)
Data (1640)
Decentralized trials (2)
Denatured (13)
Depression (45)
Diabetes (231)
Diagnostics (5542)
Digital health (17)
Diversity (4)
Diversity, equity & inclusion (42)
Drug discovery (95)
Drug pricing (117)
Drug shortages (29)
Duchenne muscular dystrophy (66)
Earnings (62988)
Editorial (34)
Employer branding (20)
Employer resources (136)
Events (83505)
Executive appointments (546)
FDA (17223)
Featured Employer (40)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (5)
Funding (558)
Gene editing (88)
Generative AI (21)
Gene therapy (274)
GLP-1 (754)
Government (4025)
Grass and pollen (4)
Guidances (43)
Healthcare (15790)
Huntington's disease (23)
IgA nephropathy (21)
Immunology and inflammation (106)
Indications (23)
Infectious disease (2754)
Inflammatory bowel disease (122)
Inflation Reduction Act (9)
Influenza (43)
Intellectual property (69)
Interviews (454)
IPO (14752)
IRA (48)
Job creations (3375)
Job search strategy (1701)
Kidney cancer (10)
Labor market (20)
Layoffs (489)
Leadership (18)
Legal (7410)
Liver cancer (70)
Lung cancer (259)
Lymphoma (121)
Machine learning (2)
Management (51)
Manufacturing (248)
MASH (59)
Medical device (11740)
Medtech (11743)
Mergers & acquisitions (15597)
Metabolic disorders (633)
Multiple sclerosis (59)
NASH (22)
Neurodegenerative disease (76)
Neuropsychiatric disorders (29)
Neuroscience (1830)
NextGen: Class of 2025 (5250)
Non-profit (3389)
Northern California (2085)
Now hiring (21)
Obesity (357)
Opinion (224)
Ovarian cancer (58)
Pain (73)
Pancreatic cancer (66)
Parkinson's disease (117)
Partnered (14)
Patents (182)
Patient recruitment (77)
Peanut (43)
People (46956)
Pharmaceutical (39)
Pharmacy benefit managers (21)
Phase I (17862)
Phase II (25776)
Phase III (20704)
Pipeline (827)
Podcasts (71)
Policy (122)
Postmarket research (2588)
Preclinical (7283)
Press Release (53)
Prostate cancer (89)
Psychedelics (35)
Radiopharmaceuticals (223)
Rare diseases (351)
Real estate (4763)
Recruiting (59)
Regulatory (21688)
Reports (29)
Research institute (2162)
Resumes & cover letters (412)
Rett syndrome (2)
RNA editing (1)
RSV (42)
Schizophrenia (68)
Series A (112)
Series B (66)
Service/supplier (11)
Sickle cell disease (51)
Southern California (1726)
Special edition (15)
Sponsored (32)
Startups (2982)
State (1)
Stomach cancer (14)
Supply chain (60)
The Weekly (58)
United States (17790)
Vaccines (708)
Venture capitalists (34)
Webinars (11)
Weight loss (272)
Women's health (29)
Worklife (16)
Date
Today (164)
Last 7 days (742)
Last 30 days (2877)
Last 365 days (32105)
2025 (5481)
2024 (32764)
2023 (36598)
2022 (47279)
2021 (50863)
2020 (47968)
2019 (38873)
2018 (29467)
2017 (29523)
2016 (27525)
2015 (30258)
2014 (23594)
2013 (19308)
2012 (20872)
2011 (21662)
2010 (20055)
Location
Africa (705)
Alabama (47)
Alaska (6)
Arizona (158)
Arkansas (9)
Asia (34841)
Australia (5811)
California (4643)
Canada (1439)
China (396)
Colorado (205)
Connecticut (246)
Delaware (110)
Europe (83281)
Florida (691)
Georgia (158)
Hawaii (1)
Idaho (41)
Illinois (403)
India (19)
Indiana (222)
Iowa (7)
Japan (122)
Kansas (82)
Kentucky (14)
Louisiana (6)
Maine (59)
Maryland (742)
Massachusetts (3574)
Michigan (168)
Minnesota (290)
Mississippi (1)
Missouri (67)
Montana (16)
Nebraska (21)
Nevada (48)
New Hampshire (52)
New Jersey (1371)
New Mexico (15)
New York (1313)
North Carolina (827)
North Dakota (6)
Northern California (2085)
Ohio (146)
Oklahoma (8)
Oregon (29)
Pennsylvania (1025)
Puerto Rico (6)
Rhode Island (23)
South America (1088)
South Carolina (13)
South Dakota (1)
Southern California (1726)
Tennessee (72)
Texas (657)
Utah (128)
Virginia (104)
Washington D.C. (54)
Washington State (442)
West Virginia (3)
Wisconsin (44)
572,783 Results for "symrise s r l".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
KRTL Holding Group Inc. Announces Milestone Achievement: FDA Registration of Industria Químico Farmaceutica SIGMA CORP. S.R.L.’s Federal Establishment Identifier
January 22, 2025
·
4 min read
Deals
Frontage Laboratories Acquires Accelera S.r.l.'s Bioanalytical and DMPK Businesses
Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera).
January 2, 2024
·
5 min read
Press Releases
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
February 19, 2025
·
9 min read
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
Ceapro Inc. announced the signing of an amendment to its long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro’s high value active ingredients to major key international players in the cosmetic market.
August 25, 2023
·
3 min read
Deals
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
Agile Therapeutics, Inc. today announced that it has entered into a definitive merger agreement (“Merger Agreement”) with Insud Pharma, S.L.
June 26, 2024
·
10 min read
Press Releases
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
December 9, 2024
·
10 min read
Press Releases
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
December 1, 2024
·
8 min read
Regulatory
Keytruda and Opdivo Scrutiny Highlights FDA’s Evolving Biomarker Focus
An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers based on PD-L1 expression levels reflects an emerging trend that leverages ever-maturing datasets.
January 13, 2025
·
5 min read
·
Kate Goodwin
FDA
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.
June 26, 2024
·
17 min read
Press Releases
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators
February 19, 2025
·
6 min read
1 of 57,279
Next
